Usefulness of head-up tilt test in evaluating patients with syncope of unknown origin and negative electrophysiologic study.
The vasovagal nature of syncope, which remained unexplained despite full clinical and electrophysiologic investigation, was evaluated by means of 60 degrees head-up tilt test for 60 minutes. Thirty patients (17 men and 13 women, mean age 65 years, 19 with and 11 without organic heart disease) with 1 to 28 (mean 5) episodes of syncope of unknown origin were studied. Head-up tilt test was considered positive if syncope developed in association with hypotension, bradycardia, or both. During baseline head-up tilt 15 patients (50%) had a positive response. Ten patients had a vasodepressor response (marked hypotension without marked bradycardia) and 5 had a mixed response (marked hypotension with marked bradycardia). None of 8 control subjects became symptomatic during the test. Baseline head-up tilt test was positively reproducible in 10 of 14 patients (71%). Nine of these 10 patients underwent serial head-up tilt tests after drug administration to determine the pathogenesis of vasovagal syncope. Atropine prevented tilt-induced syncope in 3 of 8 patients (37.5%), propranolol in 2 of 8 (25%) and etilephrine in 7 of 7 (100%). Seven patients received long-term drug treatment with drugs selected on the basis of acute drug testing. One responder to atropine received transdermal scopolamine and 6 received etilephrine. None of these 7 patients had syncopal recurrences or death during a mean follow-up of 12 months. Head-up tilt is a very sensitive and highly specific test to unmask susceptibility to vasovagal reaction in patients with syncope of unknown origin. Withdrawal of alpha-sympathetic stimulation is a principal mechanism responsible for vasodilation and syncope during head-up tilt.(ABSTRACT TRUNCATED AT 250 WORDS)
Raviele
A
A
Division of Cardiology, Umberto I Hospital, Mestre, Venice, Italy.
Gasparini
G
G
Di Pede
F
F
Delise
P
P
Bonso
A
A
Piccolo
E
E
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000368:Aged; D001285:Atropine / Q000627:therapeutic use; D001919:Bradycardia / Q000209:etiology*; D004562:Electrocardiography; D004594:Electrophysiology; D005260:Female; D006321:Heart / Q000503:physiopathology*; D006801:Humans; D007024:Hypotension, Orthostatic / Q000209:etiology*; D008297:Male; D011187:Posture; D011433:Propranolol / Q000627:therapeutic use; D013575:Syncope / Q000209:etiology* / Q000517:prevention & control
D000316:Adrenergic alpha-Agonists; D001285:Atropine; D011433:Propranolol